Protocols

Soon-Shiong blasts back at “maliciously false” STAT story; ImmunoMet raises $5M

→ Badly wounded by a report from STAT that he essentially funneled revenue to his company through a charitable gift to the University of Utah, Patrick Soon-Shiong is firing back in the LA Times, saying the story is “maliciously false.” He adds that he gave the money to the university out of a “desire to make this knowledge available to scientists throughout the world.” The report carved out a big chunk of NantHealth’s share price $NH earlier in the week. Soon-Shiong is the second largest shareholder in the company that owns the LA Times.

→ Houston-based ImmunoMet Therapeutics raised $5 million in a Series B financing with participation from Intervest, SL Investment, NHN Investment along with the Series A investors Mirae Asset Venture Investments, GNTech and Dr. Sung-wuk Kim, founder, chairman and CEO of ImmunoMet.

→ The microcap penny stock biotech Heat Biologics $HBTX has come up with a deal to buy Austin-based Pelican Therapeutics, agreeing to pay up to $500,000 for an 80% share of the company.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Associate Director CMC
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->